Epidiolex
Epidiolex
Generic Name
Epidiolex
Mechanism
Epidiolex is a purified, purified‑quality cannabidiol (CBD) formulation. Its antiepileptic effects are mediated through a multifaceted, low‑potency interaction with the endocannabinoid system and several non‑cannabinoid targets:
• Modulation of GPR55 and TRPV1 receptors – reduces excitotoxic signaling.
• α2‑adrenergic potentiation – enhances inhibitory GABAergic tone.
• Synthesis inhibition of arachidonic acid metabolites – dampens pro‑seizure lipid mediators.
• Inhibition of hepatic CYP2C19 – increases systemic exposure to other medications but does not alter seizure control directly.
These actions culminate in reduced neuronal hyperexcitability and lower seizure frequency in treatment‑resistant epilepsy.
Pharmacokinetics
| Parameter | Typical Values | Notes |
| Absorption | Gc ~ 15–23 % (oral), rapid rise within 3‑4 h | Food enhances bioavailability; with ≥300 mg dose, 60 % higher AUC with high‑fat meal |
| Distribution | Volume of distribution ~ 2.4 L/kg (high lipid solubility) | Crosses blood‑brain barrier efficiently |
| Metabolism | Hepatic oxidation via CYP3A4, CYP2C19, CYP2J2 | Inhibits CYP2C19 → potential drug interactions |
| Elimination | 40 % renal, 60 % fecal; half‑life ~ 5–7 h (steady‑state ~ 12 h) | Extended half‑life in hepatic impairment |
| Special Populations |
• Renal: unchanged; small impact on dosing • Hepatic: titrate slower, monitor LFTs | No dialysis clearance |
Indications
- Dravet syndrome (DS) – ≥6 yr, drug‑resistant seizures, accepted dosing up to 50 mg/kg/day.
- Elderly with Lennox‑Gastaut syndrome (LGS) – ≥6 yr, adjunct therapy.
- Tuberous sclerosis complex‑associated epilepsy – adjunctive for focal seizures.
- Primary/secondary generalized seizures in patients with concomitant neuro‑oncology (off‑label, limited evidence).
Contraindications
- Contraindicated in patients with known hypersensitivity to CBD or excipients.
- Precautions:
- Severe hepatic impairment (ALT > 3× ULN).
- Concomitant use of CYP2C19 inhibitors (e.g., fluconazole) or strong CYP3A4 substrates (e.g., clobazam).
- Pregnancy – limited data; risk/benefit assessment required.
- Breastfeeding – excretion in milk; decision by prescriber.
Dosing
- Start: 2.5 mg/kg/day in two divided doses (max 12.5 mg/kg/day).
- Titration: Increase by 2.5 mg/kg every 2 weeks; target 5–12.5 mg/kg/day.
- Max: 50 mg/kg/day (DS) or 100 mg/kg/day (LGS).
- Form: Oral solution – 5 mg/mL; use syringes or droppers for accuracy.
- Administration: Call in meals to optimize absorption; if patient vomits within 15 min, re‑dose with a portion of next scheduled dose.
Adverse Effects
| Class | Incidence | Notes |
| Somnolence / dizziness | 20–35% | May impair driving; monitor tolerance. |
| Fatigue | 15–25% | Often improves after steady‑state achieved. |
| Diarrhea / GI upset | 10–15% | Water‑based diet may help. |
| Elevated transaminases | 7–15% | Monitor biochemistries every 4–6 weeks initially. |
| Liver failure (rare) | <0.1% | Report immediately. |
| Respiratory depression | <0.1% | More likely with opioids / benzodiazepines. |
| Myopathy / CK elevation | <0.1% | Especially with statins. |
| Allergic dermatitis | <0.1% | Usually mild, treat with antihistamines. |
Monitoring
- Baseline:
- CBC, LFTs, metabolic panel, vitamin D, calcium, creatinine kinase.
- Seizure frequency diary (30 days pre‑treatment).
- Review concurrent medications.
- During Therapy:
- LFTs every 4‑6 weeks, then every 3 months once stable.
- CBC every 3‑6 months (statin co‑therapy).
- Seizure logs maintained by patient/guardian.
- If on Clobazam:
- Check thienodiazepine plasma levels 4–6 weeks after dose change.
- Adverse Event Reporting:
- Immediate action for signs of liver failure (jaundice, severe abdominal pain).
Clinical Pearls
- Food Interaction – A 30‐minute meal with ≥30 % fat boosts bioavailability; start administration after 1 hour when fasting.
- Clobazam Stewardship – CBD substantially increases clobazam levels. Begin clobazam at a lower dose (e.g., 0.5 mg/kg/d) and titrate conservatively to mitigate risk of somnolence.
- Rapid Titration in Dravet – Some patients stabilize within 2–3 weeks of dose escalation; early use of tele‑monitoring can reduce outpatient visits.
- Liver Enzymes & CYP2C19 – In pediatric patients with mild hepatic disease, lower initial doses (~1.5 mg/kg/day) prove safe and effective.
- Drug–Drug Interactions – Pre‑emptively check CYP2C19 genotype; poor metabolizers may need lower clobazam doses.
- Non‑seizure Benefits – Anecdotal reports of improved mood and sleep quality; monitor subjective improvement in patient-reported outcomes.
- Insurance & Cost – Prior authorization often required; note that generic‑like drug of this class is not available; specialists may rent/lease or use manufacturer patient assistance programs.
--
• _Epidiolex is a clinically validated, FDA‑approved cannabinoid treatment with a unique profile requiring vigilant monitoring. By integrating the above guidelines, you can optimize therapeutic outcomes while mitigating risks in patients with refractory epilepsy._